Steroid News and Research

RSS

Chest: January news briefs

New research suggests that subcutaneous omalizumab is safe and effective an add-on treatment to corticosteroids for moderate to severe asthma in children and adults. Researchers from Uruguay, Argentina, and Chile performed a meta-analysis on eight trials where 1,883 patients received omalizumab and 1,546 received a placebo.

4 Jan 2011

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

A multidisciplinary clinical practice guideline, "Tonsillectomy in Children" will be published in the January issue of Otolaryngology-Head and Neck Surgery.

3 Jan 2011

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

New study contradicts presence of oxysterols in multiple sclerosis patients

New research findings appearing in the January Journal of Lipid Research indicate that compounds called oxysterols are not present in any significant amount in multiple sclerosis patients, contradicting a previous study that suggested that some of these cholesterol metabolites were associated with MS and could be used as diagnostic tools in the clinic.

16 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

In people who develop symptoms of inflammatory arthritis, early diagnosis and treatment can have a significant impact on the course of disease—in some cases even preventing deformity and loss of function from rheumatoid arthritis, according to an article in the December issue of JCR: Journal of Clinical Rheumatology.

14 Dec 2010

Early physical therapy associated with fewer subsequent injections, surgery, physician visits: Study

The American Physical Therapy Association is pointing to a new study on low back pain in Medicare patients in its efforts to encourage the newly established Center for Medicare and Medicaid Innovation to promptly launch a demonstration project on direct access to physical therapist services that was recommended in the recent health reform law.

7 Dec 2010

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

ABI therapy effective for treating microtears in hamstring injury: Study

Researchers in London say they have found an effective two-part treatment for microtears in the hamstring: injections of the patient's own blood and a steroid along with "dry-needling," in which repeated needle punctures cause controlled internal bleeding in the injured area. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Study suggests less than 10% of UK adults with CAH receive specialist endocrine care

A new study suggests that less than 10% of the estimated 3,591 adults in the UK with the genetic condition congenital adrenal hyperplasia (CAH) receive specialist endocrine care, and that there is no standard treatment for these patients.

26 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Noninvasive method to determine estrogen levels in infants through diapers

With the help of babies and more than 5,000 of their diapers, Emory University researchers have developed an accurate, noninvasive method to determine estrogen levels in infants.

17 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

ICS/LABA combination therapy increases asthma-related pharmacy cost

Researchers find inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination products are commonly used by patients with mild asthma, despite the lack of evidence or guidelines for such use.

15 Nov 2010

Researchers find structural deficits in gray matter may be associated with daytime sleepiness

Patients with obstructive sleep apnea (OSA) may blame their daytime difficulties on simple sleepiness, but new research suggests that their brains may be to blame. Specifically, their cognitive challenges may be caused by structural deficits in gray matter, brought on by the intermittent oxygen deprivation that comes with OSA. The good news is that these deficits may be partially or fully reversible with early detection and treatment, according to Italian researchers

15 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis. PMI-001 is presently in Phase 2b/3 development.

9 Nov 2010

Steroid News and Research

Chest: January news briefs

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

New study contradicts presence of oxysterols in multiple sclerosis patients

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

Early physical therapy associated with fewer subsequent injections, surgery, physician visits: Study

No overall cancer risk in people who donate stem cells

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

ABI therapy effective for treating microtears in hamstring injury: Study

Study suggests less than 10% of UK adults with CAH receive specialist endocrine care

VYTORIN reduces major vascular events in patients with chronic kidney disease

Noninvasive method to determine estrogen levels in infants through diapers

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

ICS/LABA combination therapy increases asthma-related pharmacy cost

Researchers find structural deficits in gray matter may be associated with daytime sleepiness

Zalicus third quarter total revenue decreases to $1.2 million

Phytomedics awarded $244,000 QTDP grant for development of RA drug

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News